Biomarkers in gastroenterology: Between hope and hype comes histopathology

American Journal of Gastroenterology

Volumn 104, Issue 5, 2009, Pages 1093-1096

  Jankowski, Janusz A ^a,b   Odze, Robert D ^c  

^a LEICESTER ROYAL INFIRMARY   (United Kingdom)

^b IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA CATENIN; BIOLOGICAL MARKER; CARCINOEMBRYONIC ANTIGEN; CHOLECYSTOKININ; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESOMEPRAZOLE; GEFITINIB; MOLECULAR MARKER; PROTEIN P16; PROTEIN P53; TRASTUZUMAB; TUMOR MARKER;

ANEUPLOIDY; BARRETT ESOPHAGUS; BIOPSY; CANCER RISK; CANCER STAGING; CARCINOGENESIS; CHEMOPROPHYLAXIS; CLINICAL PRACTICE; CLINICAL TRIAL; COLON CANCER; COLON POLYPOSIS; COLON RESECTION; COLORECTAL CANCER; DIGESTIVE SYSTEM CANCER; DIGESTIVE SYSTEM INFLAMMATION; DYSPLASIA; EPIGENETICS; ESOPHAGEAL ADENOCARCINOMA; GENE MUTATION; GENETIC POLYMORPHISM; HISTOPATHOLOGY; HUMAN; METHYLATION; PATHOGENESIS; PREDICTION; PRIORITY JOURNAL; REVIEW; SQUAMOUS CELL CARCINOMA; STOMACH ADENOCARCINOMA; ULCERATIVE COLITIS; COLORECTAL TUMOR; ESOPHAGUS TUMOR; FEMALE; GASTROENTEROLOGY; GASTROINTESTINAL TUMOR; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION; GENETICS; IMMUNOHISTOCHEMISTRY; MALE; MOLECULAR BIOLOGY; NEEDLE BIOPSY; PATHOLOGY; PRECANCER; PREVALENCE; REPRODUCIBILITY; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; STANDARD; STOMACH TUMOR; TUMOR SUPPRESSOR GENE;

BIOLOGICAL MARKERS; BIOPSY, NEEDLE; COLORECTAL NEOPLASMS; ESOPHAGEAL NEOPLASMS; FEMALE; GASTROENTEROLOGY; GASTROINTESTINAL NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, APC; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MOLECULAR BIOLOGY; PRECANCEROUS CONDITIONS; PREVALENCE; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 66949128313     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2008.172     Document Type: Review

References (14)

1. Odze RD (ed). Gastrointestinal Clinics of North America. Elsevier: Philadelphia, 2007.
2. Riddell RH, Goldman H, Ransohoff DF et al. Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. Hum Pathol 1983;14:931-68.
3. Bernstein CN, Shanahan F, Weinstein WM. Are we telling patients the truth about surveillance colonoscopy in ulcerative colitis? Lancet 1994;343:71-4.
4. Reid BJ, Levine DS, Longton G et al. Predictors of progression to cancer in Barrett's esophagus: baseline flow cytometric variables. Am J Gastroenterol 2001;96:3071-83.
5. Thomas T, Abrams KA, Robinson RJ et al. Meta-analysis: cancer risk of low-grade dysplasia in chronic ulcerative colitis. Aliment Pharmacol Ther 2007;25:657-68.
6. Rubin CE, Haggitt RC, Burmer GC et al. DNA aneuploidy in colonic biopsies predicts future developments of dysplasia in ulcerative colitis. Gastroen-terology 1992;103:1611-20.
7. Jass JR, Whitehall VL, Young J et al. Emerging concepts in colorectal neoplasia. Gastroenterology 2002;123:862-76.
8. Winawer SJ, Zauber AG, Fletcher RH et al. Guidelines for colonoscopy surveillance after polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer and the American Cancer Society. Gastroenterology 2006;130:1872-85.
9. Gupta R, Harpaz N, Itzkowitz S et al. Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology 2007;133:1099-105.
10. El-Omar EM, Rabkin CS, Gammon MD et al. Increased risk of noncardia gastric cancer associated with proinflammatory cytokine gene polymorphisms. Gastroenterology 2003;124:1193-201.
11. Jankowski JA, Hawk ET. A methodologic analysis of chemoprevention and cancer prevention strategies for gastrointestinal cancer. Nat Clin Pract Gastroenterol Hepatol 2006;3:101-ll.
12. Preston SL, Jankowski JA. Drinking from the fountain of promise: bio markers in the surveillance of Barretfs oesophagus - the glass is half full! Gut 2006;55:1377-9.
13. Kelloff GJ, Lippman SM, Dannenberg AJ et al. Progress in chemoprevention drug development: the promise of molecular biomarkers for the prevention of intraepithelial neoplasia and cancer - a plan to move forward. Clin Can Res 2006;12:3661-97.
14. Prasad GA, Wang KK, Hailing KC et al. Utility of biomarkers in prediction of response to ablative therapy in Barretfs esophagus. Gastroenterology 2008;135:370-9.